natgillin/translations-raw huggingface dataset:
Det aktive stof i Pritor, telmisartan, er en angiotensin II- receptorantagonist, hvilket betyder, at den blokerer virkningen af et hormon i kroppen, der kaldes angiotensin II.
The active substance in Pritor, telmisartan, is an ‘ angiotensin II receptor antagonist’, which means that it blocks the action of a hormone in the body called angiotensin II.
Dette medfører, at blodtrykket falder, og risikoen for skade forårsaget af forhøjet blodtryk, såsom slagtilfælde, reduceres.
By blocking the receptors to which angiotensin II normally attaches, telmisartan stops the hormone having an effect, allowing the blood pressure to drop, reducing the risk caused by high blood pressure, such as having a stroke.
Pritor blev undersøgt hos 1 647 patienter, som blev behandlet med telmisartan alene eller i kombination med hydrochlorothiazid.
Pritor has been studied in 1,647 patients who were treated with telmisartan either alone or in combination with hydrochlorothiazide.
Pritor blev sammenlignet med placebo (et virkningsløst præparat) og med lægemidler mod forhøjet blodtryk (atenolol, lisinopril, enalapril, amlodipin).
Pritor was compared with placebo (a dummy treatment) and with other medicines for hypertension (atenolol, lisinopril, enalapril and amlodipine).
Reproduction is authorised provided the source is acknowledged Hvilken fordel viser undersøgelserne, at der er ved Pritor?
Reproduction is authorised provided the source is acknowledged.
Den fuldstændige liste over alle de indberettede bivirkninger ved Pritor fremgår af indlægssedlen.
For the full list of all side effects reported with Pritor, see the Package Leaflet.
Pritor bør ikke anvendes af personer, som kan være overfølsomme (allergiske) over for telmisartan eller et af de øvrige indholdsstoffer.
Pritor should not be used in people who may be hypersensitive (allergic) to telmisartan or any of the other ingredients.
Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Pritor er større end risiciene ved behandling af essentiel hypertension hos voksne.
The Committee for Medicinal Products for Human Use (CHMP) decided that Pritor’ s benefits are greater than its risks for the treatment of essential hypertension in adults.
Udvalget anbefalede udstedelse af markedsføringstilladelse for Pritor.
The Committee recommended that Pritor be given marketing authorisation.
Andre oplysninger om Pritor:
Other information about Pritor:
Europa- Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Pritor den 11. december 1998.
The European Commission granted a marketing authorisation valid throughout the European Union for Pritor on 11 December 1998.
Markedsføringstilladelsen blev fornyet den 11. december 2003 og den 11. december 2008.
The marketing authorisation was renewed on 11 December 2003 and on 11 December 2008.
Den fuldstændige EPAR for Pritor findes her.
The full EPAR for Pritor is available here.
Dette sammendrag blev sidst ajourført i 12 - 2008.
This summary was last updated in 12-2008.
Tabletter Tabletter Tabletter Tabletter Tabletter Tabletter Tabletter Tabletter Tabletter Tabletter Tabletter Tabletter Tabletter Tabletter Tabletter Tabletter Tabletter Tabletter Tabletter Tabletter Tabletter Tabletter
Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet
Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC)
blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC)
14 tabletter 28 tabletter 56 tabletter 98 tabletter 280 tabletter 14 tabletter 28 tabletter 56 tabletter 98 tabletter 280 tabletter 14 tabletter 28 tabletter 56 tabletter 98 tabletter 28 x 1 tabletter 28 x 1 tabletter 90 tabletter 90 tabletter 90 tabletter 30 tabletter 30 tabletter 30 tabletter
14 tablets 28 tablets 56 tablets 98 tablets 280 tablets 14 tablets 28 tablets 56 tablets 98 tablets 280 tablets 14 tablets 28 tablets 56 tablets 98 tablets 28 x 1 tablets 28 x 1 tablets 90 tablets 90 tablets 90 tablets 30 tablets 30 tablets 30 tablets
Børn Kinzalmono bør ikke anvendes til børn og unge under 18 år på grund af utilstrækkelig dokumentation for sikkerhed og virkning.
Paediatric patients Pritor is not recommended for use in children below 18 years due to a lack of data on safety and efficacy.
4. 3), idet telmisartan overvejende udskilles med galden.
Pritor is not to be given to patients with cholestasis, biliary obstructive disorders or severe hepatic impairment (see section 4.3) since telmisartan is mostly eliminated with the bile.
Der bør udvises forsigtighed, når Kinzalmono bruges til patienter med let til moderat nedsat leverfunktion.
Pritor should be used only with caution in patients with mild to moderate hepatic impairment.
Når Kinzalmono anvendes til patienter med nedsat nyrefunktion, anbefales periodisk kontrol af serumniveauerne for kalium og kreatinin.
When Pritor is used in patients with impaired renal function, periodic monitoring of potassium and creatinine serum levels is recommended.
Der er ingen erfaring med anvendelse af Kinzalmono til patienter, der kort tid forinden har fået foretaget en nyretransplantation.
There is no experience regarding the administration of Pritor in patients with recent kidney transplantation.
Specielt efter den første dosis af Kinzalmono kan der forekomme symptomatisk hypotension hos patienter, som har for lavt volumen i blodbanen eller natriummangel på grund af kraftig diuretisk behandling, saltfattig diæt, diarré eller opkastning.
Symptomatic hypotension, especially after the first dose of Pritor, may occur in patients who are volume and/ or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea, or vomiting.
Sådanne tilstande bør korrigeres før behandling med Kinzalmono.
Such conditions should be corrected before the administration of Pritor.
Volumen - og/ eller natriumdepletering bør korrigeres før behandling med Kinzalmono.
Volume and/ or sodium depletion should be corrected prior to administration of Pritor.
Patienter med sjælden arvelig fruktoseintolerans bør ikke tage Kinzalmono.
Patients with rare hereditary problems of fructose intolerance should not take Pritor.
Der foreligger ikke tilstrækkelige data om brugen af KINZALMONO hos gravide kvinder.
There are no adequate data from the use of Pritor in pregnant women.
Brystsmerter, Influenzalignende symptomer Manglende virkning af lægemidlet
Drug ineffective
Polyamid/ aluminium/ PVC blisterpakning
One blister contains 7 or 10 tablets.
14 tabletter 28 tabletter 30 tabletter 56 tabletter 90 tabletter 98 tabletter
Blister with 14, 28, 30, 56, 90 or 98 tablets.
EU/ 1/ 98/ 089/ 011 (14 tabletter) EU/ 1/ 98/ 089/ 012 (28 tabletter) EU/ 1/ 98/ 089/ 020 (30 tabletter) EU/ 1/ 98/ 089/ 013 (56 tabletter) EU/ 1/ 98/ 089/ 019 (90 tabletter) EU/ 1/ 98/ 089/ 014 (98 tabletter)
EU/ 1/ 98/ 089/ 011 (14 tablets) EU/ 1/ 98/ 089/ 012 (28 tablets) EU/ 1/ 98/ 089/ 020 (30 tablets) EU/ 1/ 98/ 089/ 013 (56 tablets) EU/ 1/ 98/ 089/ 019 (90 tablets) EU/ 1/ 98/ 089/ 014 (98 tablets)
15. september 1999 Dato for forlængelse af markedsføringstilladelse:
11 December 1998 Date of last renewal:
Hvide aflange tabletter, hvori firmaets logo og koden 51H er præget.
White oblong tablets engraved with the code number '51H '' on one side.
Børn Pritor bør ikke anvendes til børn og unge under 18 år på grund af utilstrækkelig dokumentation for sikkerhed og virkning.
Paediatric patients Pritor is not recommended for use in children below 18 years due to a lack of data on safety and efficacy.
Specielt efter den første dosis af Pritor kan der forekomme symptomatisk hypotension hos patienter, som har for lavt volumen i blodbanen eller natriummangel på grund af kraftig diuretisk behandling, saltfattig diæt, diarré eller opkastning.
Symptomatic hypotension, especially after the first dose of Pritor, may occur in patients who are volume and/ or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea, or vomiting.
Volumen - og/ eller natriumdepletering bør korrigeres før behandling med Pritor.
Volume and/ or sodium depletion should be corrected prior to administration of Pritor.
4. 8).
In patients whose vascular tone and renal function depend predominantly on the activity of the renin- angiotensin-aldosterone system (e. g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with medicinal products that affect this system such as telmisartan, has been associated with acute hypotension, hyperazotaemia, oliguria, or rarely acute renal failure (see section 4.8).
Patienter med sjælden arvelig fruktoseintolerans bør ikke tage Pritor.
Patients with rare hereditary problems of fructose intolerance should not take Pritor.
14 Kaliumbesparende diuretika eller kaliumtilskud:
14 Concomitant use not recommended
Der foreligger ikke tilstrækkelige data om brugen af PRITOR hos gravide kvinder.
There are no adequate data from the use of Pritor in pregnant women.
17 Laboratorieundesøgelser
17
14 tabletter 28 tabletter 30 tabletter 56 tabletter 90 tabletter 98 tabletter 280 tabletter
Blister with 14, 28, 30, 56, 90, 98 or 280 tablets or perforated unit dose blisters with 28 x 1 tablets.
EU/ 1/ 98/ 089/ 001 (14 tabletter) EU/ 1/ 98/ 089/ 002 (28 tabletter) EU/ 1/ 98/ 089/ 021 (30 tabletter) EU/ 1/ 98/ 089/ 003 (56 tabletter) EU/ 1/ 98/ 089/ 017 (90 tabletter) EU/ 1/ 98/ 089/ 004 (98 tabletter) EU/ 1/ 98/ 089/ 005 (280 tabletter) EU/ 1/ 98/ 089/ 015 (28 x 1 tablet)
EU/ 1/ 98/ 089/ 001 (14 tablets) EU/ 1/ 98/ 089/ 002 (28 tablets) EU/ 1/ 98/ 089/ 021 (30 tablets) EU/ 1/ 98/ 089/ 003 (56 tablets) EU/ 1/ 98/ 089/ 017 (90 tablets) EU/ 1/ 98/ 089/ 004 (98 tablets) EU/ 1/ 98/ 089/ 005 (280 tablets) EU/ 1/ 98/ 089/ 015 (28 x 1 tablets)
11. december 1998 Dato for forlængelse af markedsføringstilladelse:
11 December 1998 Date of last renewal:
21 10.
21 1.
Børn Pritor bør ikke anvendes til børn og unge under 18 år på grund af utilstrækkelig dokumentation for sikkerhed og virkning.
Pritor is not recommended for use in children below 18 years due to a lack of data on safety and efficacy.
24 Aorta - og mitralklapstenose, obstruktiv hypertrofisk kardiomyopati:
23 Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy:
Lægemidler, der kan udløse hyperkaliæmi er kaliumholdige saltsubstitutter, kaliumbesparende diuretika, ACE- hæmmere, angiotensin II- receptorantagonister, non steroide antiinflammatoriske lægemidler (NSAIDs, herunder selektive COX- 2- hæmmere), heparin, immunosuppressiva (cyclosporin eller tacrolimus) og trimethoprim. − Tilstødende komplikationer, især dehydrering, akut hjertedekompensation, metabolsk acidose, forværring af nyrefunktionen, akut forværring af nyrernes tilstand (f. eks. ved infektiøse sygdomme), cellenedbrydning (f. eks. ved akut ekstremitetiskæmi, rabdomyolyse, større traumer).
Medicinal products or therapeutic classes of medicinal products that may provoke hyperkalaemia are salt substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non steroidal anti-inflammatory drugs (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim.
Nedenstående kombinationer frarådes.
24 Concomitant use not recommended
25 Kaliumbesparende diuretika eller kaliumtilskud:
Potassium sparing diuretics or potassium supplements:
Angotensin II- receptorantagonister, såsom telmisartan, mindsker diuretisk fremkaldt kaliumtab.
Angiotensin II receptor antagonists attenuate diuretic induced potassium loss.
27 Metabolisme og ernæring
Metabolism and nutrition disorders
28 Laboratorieundesøgelser
27 Investigations
29 Hos patienter med hypertension reducerer telmisartan både det systoliske og det diastoliske blodtryk uden at påvirke pulsen.
28 In patients with hypertension telmisartan reduces both systolic and diastolic blood pressure without affecting pulse rate.
30 Telmisartans farmakokinetikske egenskaber er ikke anderledes hos ældre patienter i forhold til de der er under 65 år.
The pharmacokinetics of telmisartan do not differ between the elderly and those younger than 65 years.
31 6. 4 Særlige opbevaringsforhold
30 6.4 Special precautions for storage
EU/ 1/ 98/ 089/ 006 (14 tabletter) EU/ 1/ 98/ 089/ 007 (28 tabletter) EU/ 1/ 98/ 089/ 022 (30 tabletter) EU/ 1/ 98/ 089/ 008 (56 tabletter) EU/ 1/ 98/ 089/ 018 (90 tabletter) EU/ 1/ 98/ 089/ 009 (98 tabletter) EU/ 1/ 98/ 089/ 010 (280 tabletter) EU/ 1/ 98/ 089/ 016 (28 x 1 tablet)
EU/ 1/ 98/ 089/ 006 (14 tablets) EU/ 1/ 98/ 089/ 007 (28 tablets) EU/ 1/ 98/ 089/ 022 (30 tablets) EU/ 1/ 98/ 089/ 008 (56 tablets) EU/ 1/ 98/ 089/ 018 (90 tablets) EU/ 1/ 98/ 089/ 009 (98 tablets) EU/ 1/ 98/ 089/ 010 (280 tablets) EU/ 1/ 98/ 089/ 016 (28 x 1 tablets)
32 33 BILAG II
31 ANNEX II
35 BILAG III
33 ANNEX III
37 OPLYSNINGER, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE
35 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
Ingen krav til opbevaringstemperatur
This medicinal product does not require any special storage conditions.
38 Opbevares i originalpakning for at beskytte mod fugt
Store in the original package in order to protect from moisture.
MAN TIR ONS TOR FRE LØR SØN
Bayer HealthCare AG (Logo)
40 OPLYSNINGER, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE
39 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
Bayer HealthCare AG, D- 51368 Leverkusen Tyskland
Bayer HealthCare AG D-51368 Leverkusen Germany
47 MINDSTEKRAV TIL OPLYSNINGER PÅ BLISTERKORT ELLER BLISTERSTRIPS
46 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
INDLÆGSSEDDEL
48 PACKAGE LEAFLET:
Pritor 20 mg tabletter Telmisartan
INFORMATION FOR THE USER Pritor 20 mg tablets Telmisartan
Virkning og anvendelse 2.
What Pritor is and what it is used for 2.
Det skal du vide, før du begynder at tage Pritor 3.
Before you take Pritor 3.
Sådan skal du tage Pritor 4.
How to take Pritor 4.
Opbevaring 6.
How to store Pritor 6.
VIRKNING OG ANVENDELSE
WHAT PRITOR IS AND WHAT IT IS USED FOR
Telmisartan er en angiotensin II- receptorantagonist.
Pritor belongs to a class of medicines known as angiotensin II receptor antagonists.
Pritor- tabletter bruges til behandling af essentiel hypertension (forhøjet blodtryk). ’ Essentiel ’ betyder, at der ikke er nogen anden sygdom, der er årsag til, at blodtrykket er forhøjet.
Pritor is used to treat essential hypertension (high blood pressure). ‘ Essential’ means that the high blood pressure is not caused by any other condition.
DET SKAL DU VIDE, FØR DU BEGYNDER AT TAGE PRITOR
BEFORE YOU TAKE PRITOR
• hvis du er overfølsom (allergisk) over for telmisartan eller et af de øvrige indholdsstoffer (se under punkt 6) • hvis du er i de sidste 6 måneder af graviditeten (se afsnit Graviditet og amning) • hvis du ammer • hvis du har alvorlige leverproblemer, såsom kolestase eller galdevejsobstruktion (problem med udskillelse af galde fra leveren eller fra galdeblæren) eller anden alvorlig leversygdom
• if you are allergic (hypersensitive) to telmisartan or any other ingredients included in Pritor tablets (see section Further information for a list of other ingredients). • during the last six months of pregnancy (see section Pregnancy and breast-feeding). • if you are breast-feeding. • if you have severe liver problems such as cholestasis or biliary obstruction (problems with drainage of the bile from the liver and gall bladder) or any other severe liver disease.
50 Vær ekstra forsigtig med at tage Pritor
Take special care with Pritor
Fortæl det til lægen, hvis du har eller har haft nogen af nedenstående sygdomme eller tilstande: • Nyresygdom eller du har fået en nyre transplantation • Nedsat blodtilstrømning til en eller begge nyrer / nyrearteriestenose) • Leversygdom • Hjerteproblemer • Aldosteronnisme (vand eller saltophobning i kroppen samtidig med ubalance i mineral sammensætningen) • For lavt blodtryk (hypotension), som kan forekomme, hvis du er dehydreret (overdrevent tab af kropsvæske) eller er i saltunderskud efter anvendelse af vanddrivende medicin, er på saltfattig kost, har diarré eller ved opkastning. • Har et højt kaliumindhold i blodet (de hyppigste årsager til dette er sukkersyge, nedsat nyrefunktion, alder over 70 år og kaliumtilskud, eller medicin, der påvirker blodets indhold af kalium) • Diabetes
49 • Renal artery stenosis (narrowing of the blood vessels to one or both kidneys). • Liver disease. • Heart trouble. • Raised aldosterone levels (water and salt retention in the body along with imbalance of various blood minerals). • Low blood pressure (hypotension), likely to occur if you are dehydrated (excessive loss of body water) or have salt deficiency due to diuretic therapy ('water tablets'), low-salt diet, diarrhoea, or vomiting. • Elevated potassium levels in your blood. • Diabetes.
Pritor kan ikke anbefales til gravide.
You must tell your doctor if you think that you are (or might become) pregnant.
Hvis Pritor tages mere end 3 måneder henne i graviditeten, kan det forårsage alvorlige fosterskader (se afsnit Graviditet og amning).
Pritor is not recommended in early pregnancy and may cause serious harm to your baby after 3 months of pregnancy (see section Pregnancy and breast-feeding).
Pritor er, som alle andre angiotensin II- receptorantagonister, mindre effektiv til at sænke blodtrykket hos sorte mennesker.
As with all other angiotensin II receptor antagonists, Pritor may be less effective in lowering the blood pressure in black patients.
Hvis du sammen med Pritor tager visse andre typer medicin, kan det være nødvendigt at ændre dosis.
In some cases you may have to stop taking one of the medicines.
Muligvis vil det være nødvendigt at stoppe brugen af anden medicin, specielt hvis der er noget af følgende:
This applies especially to the medicines listed below taken at the same time with Pritor:
• Medicin, som indeholder lithium til behandling af depression. • Medicin, som kan forhøje blodets indhold af kalium, såsom kaliumholdige saltsubstitutter, kaliumbesparende medicin (visse typer diuretika eller vanddrivende tabletter) ACE- hæmmere, angiotensin II- recptorantagonister, non steroid antiinflammatoriske medicintyper (NSAID´er som aspirin og ibuprofen), heparin, lægemidler der undertrykker immunsystemet (som cyclosporin og tacrolimus) og antibiobica indeholdende trimethoprim. • Vanddrivende medicin (diuretica) i høje doser kan føre til overdrevent tab af kropsvæske og for lavt blodtryk (hypotension).
• Lithium containing medicines to treat some types of depression. • Medicines that may increase blood potassium levels such as salt substitutes containing potassium, potassium-sparing diuretics (certain'water tablets'), ACE inhibitors, angiotensin II receptor antagonists, NSAIDs (non steroidal anti-inflammatory medicines, e. g. aspirin or ibuprofen), heparin, immunosuppressives (e. g. cyclosporin or tacrolimus), and the antibiotic trimethoprim. • Diuretics ('water tablets'), especially if taken in high doses together with Pritor, may lead to excessive loss of body water and low blood pressure (hypotension).
Den blodtrykssænkende virkning med Pritor kan, ligesom ved anden blodtrykssænkende medicin, blive mindre, hvis du samtidig tager medicin mod gigt og lette smerter (non- steroid antiinflammatorisk medicin (NSAID) såsom aspirin eller ibuprofen) eller kortikosteroider.
As with other blood pressure lowering medicines, the effect of Pritor may be reduced when you take NSAIDs (non steroidal anti-inflammatory medicines, e. g. aspirin or ibuprofen) or corticosteroids.
Pritor kan øge den blodtryksnedsættende virkning af andre blodtryksnedsættende lægemidler.
Pritor may increase the blood pressure lowering effect of other medicines used to treat high blood pressure.
Brug af Pritor sammen med mad og drikke
Taking Pritor with food and drink
Tabletterne kan både tages sammen med mad og alene.
You can take Pritor with or without food.
51 Graviditet og amning
Pregnancy and breast-feeding
Pritor kan forårsage alvorlig fosterskade, hvis det tages mere end 3 måneder henne i graviditeten.
Usually, your doctor will advise you to take another medicine instead of Pritor, as Pritor is not recommended in early pregnancy, and may cause serious harm to your baby if it is used after 3 months of pregnancy.
Pritor bør derfor ikke bruges mellem tredje og niende graviditetsmåned.
Appropriate antihypertensive drug must usually replace Pritor before starting a pregnancy.
Passende blodtrykssænkende medicin bør erstatte Pritor før en graviditet.
Pritor should not be used during the second and third trimester of pregnancy.
Normalt vil lægen anbefale, at du straks stopper med at tage Pritor, hvis du bliver gravid.
50 Your doctor will normally advise you to stop taking Pritor as soon as you know you are pregnant.
Kontakt lægen, hvis du bliver gravid og er i behandling med Pritor.
If you become pregnant during therapy with Pritor, please inform and see your doctor without delay.
Du bør ikke tage Pritor, hvis du ammer.
You must not take Pritor if you are breast-feeding.
Der er ikke nogen viden om Pritor påvirker din evne til at køre bil eller betjene maskiner.
No information is available on the effect of Pritor on the ability to drive or operate machinery.
Vigtig information om nogle af de øvrige indholdsstoffer i Pritor
Important information about some of the ingredients of Pritor
SÅDAN SKAL DU TAGE PRITOR
HOW TO TAKE PRITOR
Den sædvanlige dosis af Pritor er 1 tablet daglig.
The usual dose of Pritor is one tablet a day.
Den normale dosering af Pritor til kontrol af blodtrykket i 24 timer er én tablet á 40 mg én gang daglig.
The usual dose of Pritor for most patients is one 40 mg tablet once a day to control blood pressure over the 24-hour period.
Pritor kan også bruges i kombination med diuretika (vanddrivende medicin) såsom hydrochlorthiazid, der har vist sig at øge den blodtryksnedsættende virkning af Pritor.
Pritor may also be used in combination with diuretics ('water tablets') such as hydrochlorothiazide which has been shown to have an additive blood pressure lowering effect with Pritor.
Hvis du har taget for mange Pritor- tabletter
If you take more Pritor than you should
BIVIRKNINGER 52 Pritor kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger.
Like all medicines, Pritor can cause side effects, although not everybody gets them.
Forekommer hos 1 til 10 patienter ud af 1. 000 • Sjældne:
These side effects may occur with certain frequencies, which are defined as follows: very common: affects more than 1 user in 10 common: affects 1 to 10 users in 100 uncommon: affects 1 to 10 users in 1,000
Hyppigheden kan ikke bestemmes ud fra de kendte data.
51 rare: affects 1 to 10 users in 10,000 very rare: affects less than 1 user in 10,000 not known: frequency cannot be estimated from the available data.
Urinvejsinfektion, øgning af antal hvide blodlegemer (eosinofili), allergiske reaktioner (såsom nældefeber, kløe, stakåndethed, hvæsende vejrtrækning, hævelse af ansigtet eller lavt blodtryk), langsom hjerterytme, udslæt, eksem, inflammation a led, manglende virkning af Pritor og hæmaglobinmangel.
Urinary tract infections, increase in certain white blood cells (eosinophilia), allergic reaction (e. g. rash, itching, difficulty breathing, wheezing, swelling of the face or low blood pressure), slow heart rate (bradycardia), drug rash, eczema (a skin disorder), inflammation of the tendons, ineffectiveness of Pritor and decreased haemoglobin (a blood protein).
OPBEVARING
HOW TO STORE PRITOR